Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Silvana Giacinti"'
Autor:
Luca Cindolo, Clara Natoli, Cosimo De Nunzio, Michele De Tursi, Maurizio Valeriani, Silvana Giacinti, Salvatore Micali, Mino Rizzo, Giampaolo Bianchi, Eugenio Martorana, Marcello Scarcia, Giuseppe Mario Ludovico, Pierluigi Bove, Anastasia Laudisi, Oscar Selvaggio, Giuseppe Carrieri, Maida Bada, Pietro Castellan, Stefano Boccasile, Pasquale Ditonno, Paolo Chiodini, Paolo Verze, Vincenzo Mirone, Luigi Schips
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-8 (2017)
Abstract Background To evaluate the safety and efficacy of abiraterone acetate (AA) in the “real life” clinical practice for men with chemotherapy-naïve metastatic castration-resistant prostate. Methods A consecutive series of patients with mCRP
Externí odkaz:
https://doaj.org/article/981184a786e2492083d7bce0054f6fa3
Multimodality treatment of brain metastases from renal cell carcinoma in the era of targeted therapy
Autor:
Maria Bassanelli, Antonella Viterbo, Michela Roberto, Silvana Giacinti, Anita Staddon, Anna Maria Aschelter, Chiara D’Antonio, Paolo Marchetti
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 8 (2016)
In patients with renal cancer, brain metastasis is associated with poor survival and high morbidity. Poor life expectancy is often associated with widespread extracranial metastases. In such patients, a multidisciplinary approach is paramount. Brain
Externí odkaz:
https://doaj.org/article/1db127d274f3416e9672d6ed9030426a
Autor:
Michela Roberto, Maria Bassanelli, Elsa Iannicelli, Silvana Giacinti, Chiara D’Antonio, Anna Maria Aschelter, Paolo Marchetti
Publikováno v:
Case Reports in Oncological Medicine, Vol 2015 (2015)
Background. Renal cell carcinoma accounts for about 2-3% of all malignant tumors. The prevalence of brain metastases from RCC is less than 20% of cases. Traditionally, whole brain radiotherapy as well as the latest stereotactic radiosurgery improves
Externí odkaz:
https://doaj.org/article/82c004c9a2f94422b5ec8f5a13c0468e
Autor:
Mariaconsiglia Ferriero, Francesco Prata, Riccardo Mastroianni, Cosimo De Nunzio, Giorgia Tema, Gabriele Tuderti, Alfredo Maria Bove, Umberto Anceschi, Aldo Brassetti, Leonardo Misuraca, Silvana Giacinti, Fabio Calabrò, Salvatore Guaglianone, Andrea Tubaro, Rocco Papalia, Costantino Leonardo, Michele Gallucci, Giuseppe Simone
Publikováno v:
Prostate Cancer and Prostatic Diseases.
Available data on medical treatment of metastatic castration resistant prostate cancer (mCRPC) support the use of more than one therapy line to delay chemotherapy. We evaluate in a longitudinal real life multicenter cohort, the oncological outcome of
Autor:
Mariaconsiglia Ferriero, Gabriele Tuderti, Umberto Anceschi, Alfredo Maria Bove, Aldo Brassetti, Leonardo Misuraca, Salvatore Guaglianone, Riccardo Mastroianni, Cosimo De Nunzio, Silvana Giacinti, Giorgia Tema, Luca Cindolo, Andrea Tubaro, Michele Gallucci, Luigi Schips, Fabio Calabrò, Giuseppe Simone
Publikováno v:
Journal of Urology. 207
Autor:
Michele Milella, Francesco Cognetti, Michela Roberto, Fabiana Letizia Cecere, Biagio Ricciuti, Viola Barucca, Maria Bassanelli, Paolo Marchetti, Silvana Giacinti, Alain Gelibter, Mario Santarelli, Enzo Maria Ruggeri, Anna Ceribelli, Enrico Cortesi, Rita Chiari, Diana Giannarelli
Background: The combination of radiotherapy (RT) and programmed death 1 inhibitors seems to increase antitumor immune responses. Objective: To assess the outcome and the role of the best combination sequence, i.e. immunotherapy given before, during,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e39a5f5f3cd3b0bd0d890188e6007d6
https://hdl.handle.net/11573/1676730
https://hdl.handle.net/11573/1676730
Autor:
Maria Bassanelli, Marina Borro, Michela Roberto, Diana Giannarelli, Silvana Giacinti, Simona Di Martino, Anna Ceribelli, Andrea Russo, Annamaria Aschelter, Stefania Scarpino, Andrea Montori, Edoardo Pescarmona, Silverio Tomao, Maurizio Simmaco, Francesco Cognetti, Michele Milella, Paolo Marchetti
Publikováno v:
Cancers
Cancers, Vol 14, Iss 178, p 178 (2022)
Cancers; Volume 14; Issue 1; Pages: 178
Cancers, Vol 14, Iss 178, p 178 (2022)
Cancers; Volume 14; Issue 1; Pages: 178
Simple Summary Our analysis of a 17-gene expression signature resulted in being significantly different among patients with clear cell renal cancer cell (ccRCC) who reported a recurrence-free survival (RFS) >5 years and patients with a RFS < 1 year.
Autor:
Mauro GACCI, Michele MARCHIONI, Piergustavo DE FRANCESCO, Clara NATOLI, Fabio CALABRÒ, Tania LOSANNO, Cito GIANMARTIN, Sergio SERNI, Laura DONI, Cosimo DE NUNZIO, Michele DE TURSI, Maurizio VALERIANI, Silvana GIACINTI, Mario ÁLVAREZ-MAESTRO, Marcello SCARCIA, Giuseppe M. LUDOVICO, Gabriella DEL BENE, Giuseppe SIMONE, Mariaconsiglia FERRIERO, Gabriele TUDERTI, Pierluigi BOVE, Anastasia LAUDISI, Giuseppe CARRIERI, Luigi CORMIO, Paolo VERZE, Roberto LA ROCCA, Mario FALSAPERLA, Viviana FRANTELLIZZI, Francesco GRECO, Marta DI NICOLA, Luigi SCHIPS, Luca CINDOLO
Publikováno v:
Minerva Urology and Nephrology. 73
Metastatic castration-resistant prostate cancer (mCRPC) is the final stage of pCa history and represents a clinically relevant phenotype with an elevated burden of mortality. The aim of the present study was to evaluate the efficacy and safety of enz
Autor:
Anna Maria Aschelter, Michela Roberto, Paolo Marchetti, Maria Bassanelli, Francesca Di Pietro, Giulia Poti, Enzo Maria Ruggeri, Silvana Giacinti, Serena Macrini, Anna Ceribelli
Publikováno v:
Anticancer Research. 38:6029-6039
Inhibiting androgen receptor (AR) signaling with androgen deprivation therapy (ADT) represents the mainstay of therapy for advanced and metastatic prostate cancer. However, about 20-60% of patients receiving first-line treatment for prostate cancer w
Autor:
Maurizio Martini, Anna Ceribelli, Stefano Sioletic, Silvana Giacinti, Antonella Viterbo, Maria Bassanelli, Anita Staddon, Fabrizio Liberati
Publikováno v:
Anticancer Research. 38:3789-3796
Immunotherapy with monoclonal antibodies against programmed cell death (PD-1), such as nivolumab and pembrolizumab, has significantly improved the survival of patients with metastatic non-small cell lung cancer (NSCLC). In order to determine the subs